Best Neurology Companies in Paris, France
The 33 best Neurology companies in Paris, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Syremis.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Paris
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Syremis Developer of novel medicines for mental health conditions 22Funding top 20%Global top 45%Talent bottom 49%Tech bottom 29% All 5 signals ▾Fundingtop 20% Globaltop 45% Talentbottom 49% Techbottom 29% Marketbottom 25% Funding: Raised $165M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 3 countries beyond France rank vs industry peers · Fliar Intelligence Index 22/100 | $165M | 10 mo ago | — | Elisabeth Kogan Co-Founder & CEO | WordPressMySQLPHP+15 | — | — |
| 2 | BioSerenity Provider of smart healthcare solutions for sleep and EEG lab management 60Moat top 19%Tech top 25%Patents top 29%Innovation top 34% All 11 signals ▾Moattop 19% Techtop 25% Patentstop 29% Innovationtop 34% Fundingtop 34% Markettop 45% Growthtop 45% Producttop 46% Newsbottom 43% Globalbottom 42% Fin. healthbottom 36% Moat: Editorial + unicorn rating 8/10 · IP moat: 140 patents Tech: 53 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 60/100 | $121M | 35 mo ago | 340 | — | WordPressApple iCloud MailMicrosoft 365+24 | 140 patents Wearable EEG and textile electrode technologies for brain activity monitoring | — |
| 3 | AB Science Developer of tyrosine kinase inhibitors for multiple disease indications 42Funding top 20%Patents top 21%Innovation top 28%Moat top 28% All 9 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 28% Moattop 28% Newstop 33% Growthtop 45% Techbottom 41% Globalbottom 38% Marketbottom 21% Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $83M | 6 mo ago | 3 | — | WordPressPleskMySQL+22 | 454 patents Small-molecule tubulin inhibitors and repurposed drugs for oncology and hematologic disorders | — |
| 4 | MedDay Pharmaceuticals Developer of therapeutics for the treatment of neurological and psychiatric diseases | $49M | 126 mo ago | 82 | — | — | 58 patents Pharmaceutical formulations targeting hepatic encephalopathy and neurodegenerative disorders | — |
| 5 | Coave Therapeutics Developer of gene therapy for ocular and neurological disease 50Funding top 33%Patents top 34%Growth top 35%Moat top 36% All 9 signals ▾Fundingtop 33% Patentstop 34% Growthtop 35% Moattop 36% Innovationtop 42% Talentbottom 49% Techbottom 44% Globalbottom 43% Marketbottom 38% Funding: Raised $44.0M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Patents: 27 patents matched (strict assignee match) · 26 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 21 mo ago | 34 | Rodolphe Clerval Chief Executive Officer | WordPressApple iCloud MailMicrosoft 365+23 | 27 patents Engineered AAV vectors with lactam/squaramide modifications for CNS gene therapy. | — |
| 6 | Acticor Biotech Developing immunotherapeutics for treating ischemic stroke | $31M | 83 mo ago | 29 | Gilles Avenard CEO | Webflow EcommerceWebflowApple iCloud Mail+13 | 58 patents GPVI-targeted antibody therapeutics for antiplatelet and cardiovascular disease treatment | — |
| 7 | Robeauté Developer of microrobots for neurosurgical applications 35Growth top 35%Talent top 38%Funding top 44%Global bottom 39% All 6 signals ▾Growthtop 35% Talenttop 38% Fundingtop 44% Globalbottom 39% Techbottom 38% Marketbottom 27% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 21 mo ago | 15 | Joana Cartocci Co-Founder & COO | WebflowApple iCloud MailMicrosoft 365+8 | — | — |
| 8 | EG 427 Developer of gene therapies for neurogenic bladder 35Talent top 28%Patents top 37%Funding top 38%Moat top 39% All 9 signals ▾Talenttop 28% Patentstop 37% Fundingtop 38% Moattop 39% Innovationtop 48% Globalbottom 43% Marketbottom 33% Techbottom 33% Newsbottom 20% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Patents: 17 patents matched (strict assignee match) · 17 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $20M | 20 mo ago | 17 | Pierre Denys Co-Founder | PleskPHPYouTube+11 | 17 patents HSV‑1 based viral vectors for gene therapy targeting bladder, brain, and spasticity | — |
| 9 | Pharmaleads Mid-clinical stage biopharma company developing small molecule therapeutics for chronic pain conditions | $14M | 148 mo ago | 10 | Dominique Bouvier CEO | — | 198 patents Peptide-based neprilysin/APN inhibitors and their large‑scale salt manufacturing processes | — |
| 10 | MITEM Pharma Developer of targeted therapies to treat multiple diseases | $11M | 54 mo ago | — | Eric Thierry Co-Founder & COO | — | — | — |
| 11 | Rest Therapeutics Developer of therapeutics for the treatment of neurological and psychiatric disorders | $5M | 30 mo ago | 6 | Gilles Rubinstenn Founder & CEO | — | 19 patents Patents concentrated in health & consumer products | — |
| 12 | ORPHELIA Pharma Developer of therapies for treating pediatric neurology, pediatric oncology, and hematology | $4M | 82 mo ago | 9 | Hugues Bienayme Founder & CEO | — | — | — |
| 13 | Julier Medical Developer of a medical device to treat acute ischemic stroke | $3M | 45 mo ago | 4 | Laurent Grandidier Co-Founder | — | — | — |
| 14 | BrainEver Developer of drug candidates to treat neurodegenerative diseases | $3M | 52 mo ago | 17 | Bernard Gilly Co-Founder & CEO | — | 4 patents Formulations stabilizing therapeutic proteins for pharmaceutical use. | — |
| 15 | Mensia Technologies A non-invasive device for the treatment of ADHD | $2M | 86 mo ago | 20 | Michel du Peloux CEO | — | — | — |
| 16 | InBrain Pharma Developer of therapeutic solutions for the treatment of neurodegenerative diseases | $1M | 17 mo ago | 4 | Matthieu Fisichella Co-Founder & CEO | — | — | — |
| 17 | Brain Vectis Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease | $1M | 121 mo ago | 5 | — | — | — | — |
| 18 | Neurallys Developing a device for the treatment of Hydrocephalus | $847K | 90 mo ago | 3 | Philippe Auvray Co-Founder & CEO | — | 11 patents Cerebrospinal fluid turbidity sensing and ventriculoperitoneal shunt malfunction detection devices | — |
| 19 | Suricog Provider of eye-tracking solutions for diagnosis and monitoring of neurological disorders | $484K | 142 mo ago | — | Marc Massonneau Co-Founder & Owner & CEO | — | 25 patents Eye tracking and ocular/facial biometric measurement technologies for diagnostic and interaction applications | — |
| 20 | NeoNeuro Provider of aptamer-based molecular diagnostics for Alzheimer's Disease | $363K | 74 mo ago | — | Gregory Penner Founder & President | — | 6 patents Aptamer-based biomarkers for early Alzheimer's disease detection | — |
| 21 | Alzohis Non-invasive diagnostics for neurodegenerative diseases | $110K | 79 mo ago | 5 | Myriam Taverna Co-Founder & CSO | — | 10 patents AI-driven diagnostic algorithms for neurodegenerative disease differentiation using biomarkers | — |
Top 12 Neurology companies in Paris
#1
Public · Paris, Ile de France · founded 2001 · 3 employees$83.2Mraised▾
Developer of tyrosine kinase inhibitors for multiple disease indications. The company's lead candidate drugs are masitinib, a highly selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer for oncology, neurodegenerative and inflammatory indications.
- May 2026Post IPO$3M
- Oct 2025Post IPO$3.3M
- Jul 2025Post IPO$2.3M
- May 2025Post IPO$2M
#2
Series A · Paris, Ile de France · founded 2017$165Mraised▾
Developer of novel medicines for mental health conditions. The company focuses on neuropsychiatric treatments rooted in clinically validated mechanisms. It advances programs for schizophrenia, psychotic disorders, major depressive disorder, and bipolar depression. The lead program is a dual agonist in Phase 1 development. Another program is a novel antagonist currently in IND-enabling studies.
- Dec 2025Series A$165M
#3
Series B · Paris, Ile de France · founded 2014 · 34 employees$44Mraised▾
Developer of gene therapy for ocular and neurological disease. The drug candidates include CTx-PDE6b for inherited retinal dystrophy, CTx-ABCA4 for Stargardt’s Disease, CTx-GBA1 for Parkinson’s, and neuronopathic Gaucher diseases. These drugs are based on the AAV-ligand conjugates platform for targeted delivery.
- Jan 2025Series B$33M
- Jul 2021Series B$39M
- Jul 2016Series A$4.4M
- Jul 2015Grant (prize money)$166.6K
#4
Seed · Paris, Ile de France · founded 2017 · 15 employees$28Mraised▾
Developer of microrobots for neurosurgical applications. The platform utilizes miniature robots to diagnose, treat, and monitor brain diseases with high precision. It aims to improve patient outcomes and advance the field of neurosurgery and for the treatment of various brain-related disorders. It is used for tasks like biopsies, drug delivery, electrode implantation, and real‑time data collection through complex 3D brain paths.
- Jan 2025Seed$28M
- Jun 2020Grant (prize money)—
#5
Series B · Paris, Ile de France · founded 2020 · 17 employees$20Mraised▾
Developer of gene therapies for neurogenic bladder. The company has an HSV-1 vector platform for the delivery and expression of a transgene encoding the light chain of botulinum toxin F in sensory neurons to treat neurogenic bladder after spinal cord injury, overactive bladder, and Interstitial cystitis.
- Feb 2025Series B$28.2M
- Jul 2023Series A$20M
#6
Series B · Paris, Ile de France · founded 2014 · 340 employees$121Mraised▾
Provider of smart healthcare solutions for sleep and EEG lab management. The company offers a comprehensive software solution that enables healthcare providers to manage sleep and EEG labs, with features such as scheduling, HST processing, and remote patient communication. Also, it offers ICECAP an EEG device for inpatient or outpatient testing.
- Nov 2023PE$25.6M
- Jun 2019Series B$74M
- Sep 2017Series A$18M
- Jun 2015Seed$3.4M
#7
Seed · Paris, Ile de France · founded 2018 · 4 employees$1.1Mraised▾
InBrain Pharma is a developer of therapeutic solutions for the treatment of neurodegenerative diseases. It has developed treatment solutions for neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, and others.
- May 2025Seed$2M
- Mar 2019Seed$1.1M
#8
Funding Raised · Paris, Ile de France · founded 2020 · 6 employees$5.3Mraised▾
Developer of therapeutics for the treatment of neurological and psychiatric disorders. The company's flagship product is FENM a biomarker of the brain receptor NMDA, as a treatment solution neurodegenerative diseases such as Alzheimer’s disease.
- May 2024Grant (prize money)$2.7M
- 2023Grant (prize money)$2.7M
#9
Public · Paris, Ile de France · founded 2013 · 29 employees$31.4Mraised▾
Developing immunotherapeutics for treating ischemic stroke. The company engages in developing therapeutic monoclonal antibodies for the treatment of ischemic strokes. It offersin developing ACT-017, a humanized antibody for the treatment of cerebral stroke and the platelet glycoprotein VI.
- Nov 2019Series B$7.8M
- Oct 2018Series B$17.7M
- Jan 2018Grant (prize money)$2.6M
- Jan 2018Series B$2M
#10
Deadpooled · Paris, Ile de France · founded 2011 · 82 employees$49.2Mraised▾
Developer of therapeutics for the treatment of neurological and psychiatric diseases. The company's product pipeline includes MD1003 to treat Progressive Multiple Sclerosis and Adrenomyeloneuropathy, MD1103 for Autism Spectrum Disorders, and MD1105 to treat Alzheimer's Disease. The company has also developed a SPECMET research platform that identifies new therapeutic targets through cerebrospinal fluid metabolomic analysis.
- Apr 2016Series B$38.7M
- Apr 2013Series A$10.5M
#11
Series B · Paris, Ile de France · founded 2016$10.8Mraised▾
Developer of targeted therapies to treat multiple diseases. The product line of the company includes Meladinine a photosensitizer for the treatment of skin conditions that include psoriasis and lesions and Propranolol for cardiac arrhythmias. Also, it develops drugs for endocrine and central nervous system diseases.
- Apr 2022Series B$10.8M
#12
Seed · Paris, Ile de France · founded 2018 · 4 employees$3.3Mraised▾
Developer of a medical device to treat acute ischemic stroke. It offers a mechanical thrombectomy device for the removal of blood clots and post-stroke revascularization.
- Jan 2023Seed$3.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neurotech in Paris is moving
A read on the academic research around Neurotech in Paris — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 196 papers.
- Assistance Publique – Hôpitaux de Paris141
- CEA Paris-Saclay17
- Université Paris-Est Créteil14
- Université Paris Cité13
- Université Paris-Saclay9
- Neuroscience4→5
- Stimulation4→5
- Neurostimulation2→8
- Anesthesia2→8
- Gait1→4
- Disease2→3
- Neurostimulation1→4
- Transcranial magnetic stimulation2→4
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.